Free Trial

Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

-1.11 (-7.02%)
(As of 07/18/2024 ET)

Enanta Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 6 Wall Street analysts who have issued ratings for Enanta Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 6 analysts, 1 has given a sell rating, 3 have given a hold rating, and 2 have given a buy rating for ENTA.

Consensus Price Target

29.16% Upside
High Forecast$27.00
Average Forecast$19.00
Low Forecast$11.00

According to the 6 analysts' twelve-month price targets for Enanta Pharmaceuticals, the average price target is $19.00. The highest price target for ENTA is $27.00, while the lowest price target for ENTA is $11.00. The average price target represents a forecasted upside of 29.16% from the current price of $14.71.

TypeCurrent Forecast
7/19/23 to 7/18/24
1 Month Ago
6/19/23 to 6/18/24
3 Months Ago
4/20/23 to 4/19/24
1 Year Ago
7/19/22 to 7/19/23
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.00$19.00$19.33$56.00
Forecasted Upside29.16% Upside46.38% Upside65.88% Upside17.49% Upside
Get Enanta Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

ENTA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ENTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Enanta Pharmaceuticals Stock vs. The Competition

TypeEnanta PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside29.16% Upside1,347.42% Upside9.16% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/7/2024HC Wainwright
3 of 5 stars
 Lower TargetBuy ➝ Buy$28.00 ➝ $27.00+104.70%
5/7/2024JMP Securities
2 of 5 stars
 Lower TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $22.00+74.05%
2/8/2024JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetUnderweight ➝ Underweight$12.00 ➝ $11.00-11.00%
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$25.00 ➝ $21.00+128.76%
10/2/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform ➝ Sector Perform$25.00 ➝ $15.00+34.29%
8/8/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$49.00 ➝ $18.00-6.93%
2/9/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform$49.00-6.95%
2/8/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$87.00+59.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:05 PM ET.

ENTA Forecast - Frequently Asked Questions

What is Enanta Pharmaceuticals' forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Enanta Pharmaceuticals is $19.00, with a high forecast of $27.00 and a low forecast of $11.00.

Should I buy or sell Enanta Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There is currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.

Does Enanta Pharmaceuticals's stock price have much upside?

According to analysts, Enanta Pharmaceuticals's stock has a predicted upside of 46.38% based on their 12-month stock forecasts.

What analysts cover Enanta Pharmaceuticals?

Enanta Pharmaceuticals has been rated by research analysts at HC Wainwright, and JMP Securities in the past 90 days.

Do Wall Street analysts like Enanta Pharmaceuticals more than its competitors?

Analysts like Enanta Pharmaceuticals less than other "medical" companies. The consensus rating for Enanta Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ENTA compares to other companies.

This page (NASDAQ:ENTA) was last updated on 7/18/2024 by Staff

From Our Partners